Vaccine (Pfizer-BioNTech) coming soon

Elaf from London: Pfizer and Biotech announced that the Corona vaccine, which has now been shown to be 95% effective, has met the safety standards necessary to obtain an emergency permit.

The two companies said they plan to submit the COVID-19 vaccine to the US Safety Standards Administration for approval for emergency use “in a few days” before sharing it with others around the world.

In London, the UK Medicines and Healthcare Products Regulatory Authority (MHRA) is preparing to speed up the vaccine licensing process, which could mean it will be rolled out to priority groups from mid-December.
A final efficacy analysis of the vaccine showed that 95% were protected from the virus within 28 days of the first dose, longer than when the results of the phase 3 trials were shared last week.

It has also been shown to be 94% effective in adults over 65, who are generally weaker. The two companies said no “serious safety concerns” were reported in the analysis, with only 2% of 43,000 people reporting headaches and 3.7% reporting fatigue.
On November 9, Pfizer became the first company in the world to complete the third phase of its coronavirus vaccine trials, which showed 90% efficacy.

لقاح موديرنا
This news was followed earlier this week by an announcement by the American pharmaceutical company Moderna that its candidate vaccine has an equally promising 94.5% efficacy.

To date, the UK government has ordered 40 million doses of the Pfizer-BioNTech syringe, enough for 20 million people, and five million, for use in 2.5 million patients, of the Modern dose.

Dr. Albert Burla, Pfizer President and CEO, said: “The study results represent an important step in this historic eight-month journey to provide a vaccine that can help end this devastating epidemic.
“We continue to advance at the speed of science to collect all the data collected so far and share it with regulators around the world,” he added.